Oncology

James A. Underberg, MD, outlined recent cardiovascular outcomes evidence for PCSK9 inhibitors and discussed strategies for improving access to therapy for appropriate patients.

James A. Underberg, MD, outlined recent cardiovascular outcomes evidence for PCSK9 inhibitors and discussed strategies for improving access to therapy for appropriate patients.

James A. Underberg, MD, outlined recent cardiovascular outcomes evidence for PCSK9 inhibitors and discussed strategies for improving access to therapy for appropriate patients.

The Cardiometabolic Risk Summit, an official meeting of Consultant360, took place September 14-16 at the Marriott San Antonio Rivercenter.

The Cardiometabolic Risk Summit, an official meeting of Consultant360, took place September 14-16 at the Marriott San Antonio Rivercenter.

The Cardiometabolic Risk Summit, an official meeting of Consultant360, took place September 14-16 at the Marriott San Antonio Rivercenter.

In his session at CRS 2018, Dr Edward Shahady discussed the importance of early recognition of diabetes, outlining appropriate prevention and treatment measures for the numerous micro- and macrovascular...

In his session at CRS 2018, Dr Edward Shahady discussed the importance of early recognition of diabetes, outlining appropriate prevention and treatment measures for the numerous micro- and macrovascular...

In his session at CRS 2018, Dr Edward Shahady discussed the importance of early recognition of diabetes, outlining appropriate prevention and treatment measures for the numerous micro- and macrovascular...